Showing results (61-70 of 121) with videos related to

Sort By:
Pageof 13
Iscience|October 6, 2025
Exploring multiorgan mitochondrial dysfunction in the switch toward progressive MASLD in AMLN miceMarica Meroni, Erika Paolini, Miriam Longo, et al.
Pituitary|March 9, 2019
The role of autoimmunity in pituitary dysfunction due to traumatic brain injuryAnnamaria De Bellis, Giuseppe Bellastella, Maria Ida Maiorino, et al.
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|April 8, 2020
Alterations in the Levels of Circulating and Endothelial Progenitor Cells Levels in Young Adults with Type 1 Diabetes: A 2-Year Follow-Up from the Observational METRO StudyMiriam Longo, Lorenzo Scappaticcio, Giuseppe Bellastella, et al.
Ejhaem|June 27, 2025
Next Generation Sequencing Allows Identification of a Novel Mutation in the TfR2 Gene and Outperforms the Conventional Diagnostic TechniquesMiriam Longo, Erika Paolini, Marica Meroni, et al.
Frontiers in Nutrition|March 20, 2023
The I148M PNPLA3 variant mitigates niacin beneficial effects: How the genetic screening in non-alcoholic fatty liver disease patients gains valueErika Paolini, Miriam Longo, Marica Meroni, et al.
International Journal of Molecular Sciences|February 26, 2020
Impact of Pituitary Autoimmunity and Genetic Disorders on Growth Hormone Deficiency in Children and AdultsGiuseppe Bellastella, Maria Ida Maiorino, Miriam Longo, et al.
Frontiers in Reproductive Health|October 28, 2022
Varicocele: An Endocrinological PerspectiveGiuseppe Bellastella, Raffaela Carotenuto, Francesco Caiazzo, et al.
Hepatology Communications|October 22, 2021
Low Lipoprotein(a) Levels Predict Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver DiseaseMarica Meroni, Miriam Longo, Rosa Lombardi, et al.
Hormones (Athens, Greece)|October 15, 2025
Immune checkpoint inhibitors and metabolic events: results from a European safety analysisMiriam Longo, Annamaria Mascolo, Gabriella di Mauro, et al.
Diabetes Care|April 22, 2021
Feasibility of Simplification From a Basal-Bolus Insulin Regimen to a Fixed-Ratio Formulation of Basal Insulin Plus a GLP-1RA or to Basal Insulin Plus an SGLT2 Inhibitor: BEYOND, a Randomized, Pragmatic TrialDario Giugliano, Miriam Longo, Paola Caruso, et al.
Pageof 13